Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers

Leukemia & Lymphoma
T BarbuiJean B Brière

Abstract

The therapeutic strategy in patients with Essential Thrombocythemia (ET) is a difficult balance between the prevention of bleeding and thrombotic complications and the risks of drug side effects and toxicity. Major bleeding is rare and seem to be related to higher platelet counts: therefore, a platelet count over 1500 x 10(9)/L is generally regarded as an indication for cytoreduction. Thrombotic complications include microvascular occlusive symptoms, which are reversible with low-dose aspirin, and large vessels thrombosis. The risk of major thrombosis is higher in ET patients aged more than 60 ys. and with previous occlusive event. In this high-risk group, the non-alkylating agent hydroxyurea (HU) significantly reduces the rate of vascular complications and has emerged as the treatment of choice. However, the long-term risk/benefit of HU remains disputed because its leukemogenic potential has not been ruled out. This holds also for other myelosuppressive agents, such as busulphan and pipobroman. Other drugs of particular interest for young patients include recombinant alpha-interferon (IFN) and Anagrelide. Both of them are effective in lowering platelet count, but their efficacy in reducing clinical complications remains to be ...Continue Reading

References

Dec 10, 1977·British Medical Journal·H StottD A Galton
May 1, 1992·American Journal of Hematology·J J PetitA Fernandez de Sevilla
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·X YataganasG Vayopoulos
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M GiraltA López-Borrasca
Aug 1, 1991·American Heart Journal·M G SchefferJ R Roelandt
Oct 1, 1991·British Journal of Haematology·H GisslingerH Ludwig
Oct 1, 1991·British Journal of Haematology·F J Giles
Oct 1, 1991·Annals of Hematology·S SacchiM F Martelli
Jan 1, 1991·American Journal of Clinical Pathology·C L BalduiniG C Piletta
Feb 1, 1991·Mayo Clinic Proceedings·K J McIntyreR M Petitt
Jan 1, 1991·The American Journal of Pediatric Hematology/oncology·M M ChintagumpalaD J Fernbach
Jun 1, 1991·British Journal of Haematology·T C Pearson
Feb 1, 1990·European Journal of Haematology·J Kutti
Jan 1, 1990·American Journal of Hematology·F E MillardG G Marino
Mar 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S CortelazzoT Barbui
May 1, 1990·American Journal of Hematology·S NandR I Fisher
Aug 1, 1990·Cancer·P FenauxF Bauters
Oct 1, 1988·European Journal of Haematology·E Löfvenberg, A Wahlin
Mar 15, 1988·Cancer·J J Lahuerta-PalaciosJ Montero-Castillo
May 19, 1988·The New England Journal of Medicine·M N SilversteinL P Schacter
Oct 1, 1986·Cancer Genetics and Cytogenetics·M De Braekeleer
Oct 1, 1986·Scandinavian Journal of Haematology·M G MazzucconiF Mandelli
Feb 1, 1986·British Journal of Haematology·J E Van de PetteG Wetherley-Mein
Oct 1, 1985·Scandinavian Journal of Haematology·B E de PauwJ Steenbergen
Feb 19, 1981·The New England Journal of Medicine·P D BerkL R Wasserman
Sep 1, 1982·British Journal of Haematology·I Brodsky
Sep 26, 1980·JAMA : the Journal of the American Medical Association·H K ShamasunderW H Knospe
Apr 27, 1995·The New England Journal of Medicine·S CortelazzoT Barbui
Aug 1, 1993·Genitourinary Medicine·M Murphy, F Mulcahy
Jan 1, 1994·Acta Haematologica·V RamettaR Cimino
Jan 1, 1994·Scandinavian Journal of Rheumatology·A J GeirssonL P Asgeirsdóttir

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Hematology·Tiziano Barbui
May 23, 1998·Blood Reviews·S Willoughby, T C Pearson
Apr 25, 2001·Pathologie-biologie·G Finazzi, T Barbui
Dec 13, 2000·European Journal of Internal Medicine·S N TsiaraK L Bourantas
May 5, 1999·Critical Reviews in Oncology/hematology·T Barbui, G Finazzi
Dec 19, 1998·British Journal of Haematology·M RuggeriT Barbui
May 8, 1999·British Journal of Haematology·H GisslingerI Pabinger
Jun 10, 2000·British Journal of Haematology·A BerrebiA Klepfish
Oct 27, 1998·Journal of Pediatric Hematology/oncology·H LacknerW Schwinger
Apr 14, 1999·Australian and New Zealand Journal of Medicine·A K MillsC Kelly
Jan 11, 2007·Orphanet Journal of Rare Diseases·Jean B Brière
Dec 2, 2006·Drugs·Elisabeth I Penninga, Ole W Bjerrum
Dec 9, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·G LiumbrunoM L Sodini
Dec 6, 2007·International Journal of Dermatology·Roeland P M CeulenPamela Poblete-Gutiérrez
Mar 10, 2005·Leukemia Research·Steven M FruchtmanUNKNOWN Anagrelide Study Group
Dec 12, 2002·Hematology·Apostolia-Maria Tsimberidou, Francis J Giles
Feb 1, 1997·Baillière's Clinical Haematology·J BriereE Peynaud-Debayle
Mar 22, 2000·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·J J Michiels
Aug 12, 1999·British Journal of Haematology·L DawsonJ C Kluin-Nelemans
Jun 8, 1999·European Journal of Haematology·O Lannemyr, J Kutti
Jan 1, 1997·Hematology·T BarbuiT C Pearson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.